Скачать с ютуб Moving beyond JAK inhibitors: novel targets and pathways being explored for the treatment of MPNs в хорошем качестве

Moving beyond JAK inhibitors: novel targets and pathways being explored for the treatment of MPNs

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses some of the novel pathways and targets that hold potential for the treatment of myeloproliferative neoplasms (MPNs) and may allow the field to move beyond JAK inhibition. Dr Masarova lists some of the agents and therapeutic approaches in the early phases of development, including PIM kinase inhibitors, tasquinimod (an HDAC and alarmin inhibitor), and immunotherapy approaches using regulatory T-cells (Tregs). This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.